Powder: -20°C for 3 years | In solvent: -80°C for 1 year
UC2288 是新型的、细胞通透性、口服有效的p21衰减试剂,基于索拉非尼的结构合成。在不依赖 于p53的情况下,它可以下调 p21 mRNA 的表达,降低 p21 蛋白水平,对 p21 蛋白的稳定性影响很小。它对VEGFR2 和 Raf 激酶没有抑制作用,即使在 10 μM。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 328 | 现货 | ||
5 mg | ¥ 828 | 现货 | ||
10 mg | ¥ 1,230 | 现货 | ||
25 mg | ¥ 2,490 | 现货 | ||
50 mg | ¥ 3,960 | 现货 | ||
100 mg | ¥ 5,650 | 现货 | ||
200 mg | ¥ 7,890 | 现货 | ||
500 mg | ¥ 11,200 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 878 | 现货 |
产品描述 | UC2288 is a relatively selective p21 attenuator which is synthesized based Sorafenib. UC2288 attenuates p21 protein levels with minimal effect on p21 protein stability. |
体外活性 | UC2288 (0-10 μM; 24 hours) decreases p21 mRNA expression transcriptionally or post-transcriptionally but independently of p53. UC2288 has no inhibition of VEGFR2 and Raf kinases even at 10 μM[1]. |
体内活性 | UC2288 (10 mg/kg; i.p.) attenuates MPTP-induced behavioral impairment, prevents activation of MAPK pathway in the MPTP-treated mice brain. MPTP treatment raises TNF-α, IL-6 and IL-1β levels in MPTP treated mice brain, but UC2288 signicantly decreases MPTP-induced TNF-α, IL-6 levels, but IL-1β is not decreased in brain[2].UC2888 (15 mg/kg; oral) co-treatment with imetelstat significantly suppresses tumor growth and does not effect mice weight[3]. |
分子量 | 481.82 |
分子式 | C20H18ClF6N3O2 |
CAS No. | 1394011-91-6 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 48 mg/mL (99.62 mM), Sonication is recommended.
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 2.0755 mL | 10.3773 mL | 20.7546 mL | 51.8866 mL |
5 mM | 0.4151 mL | 2.0755 mL | 4.1509 mL | 10.3773 mL | |
10 mM | 0.2075 mL | 1.0377 mL | 2.0755 mL | 5.1887 mL | |
20 mM | 0.1038 mL | 0.5189 mL | 1.0377 mL | 2.5943 mL | |
50 mM | 0.0415 mL | 0.2075 mL | 0.4151 mL | 1.0377 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
UC2288 1394011-91-6 Apoptosis Mdm2 p53 Attenuator 786-O Inhibitor MDM-2/p53 UC 2288 inhibit ovarian RCC HK2 p21 sorafenib UC-2288 p53-mutant cancer inhibitor